You're browsing as a guest. Sign in to unlock all features.
AKTS
Aktis Oncology·Biotechnology·United States
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radi...
1 Total1 External0 In-site
AKTSAktis Oncology
2026-01-08🏥 HealthcarePitch
Externalby Anders Research · Substack
Aktis Oncology (AKTS): Largest Biotech IPO in Two Years and Likely to be Acquired
Aktis Oncology is developing alpha particle-emitting radiopharmaceuticals for the treatment of multiple solid tumor types. The company's lead asset, AKY-1189, targets Nectin-4 and has the potential to be a multi-cancer radiopharmaceutical. The company is expected to have a successful IPO and is a likely acquisition target.